163 related articles for article (PubMed ID: 3584851)
1. Rebound elevation of cortisol following cyproheptadine withdrawal in Cushing's disease from a pituitary macroadenoma.
Ooi TC; Twum-Barima Y
J Endocrinol Invest; 1987 Apr; 10(2):107-9. PubMed ID: 3584851
[TBL] [Abstract][Full Text] [Related]
2. Cyproheptadine treatment in Cushing's disease.
Tanakol R; Alagöl F; Azizlerli H; Sandalci O; Terzioğlu T; Berker F
J Endocrinol Invest; 1996 Apr; 19(4):242-7. PubMed ID: 8862505
[TBL] [Abstract][Full Text] [Related]
3. Cyproheptadine-induced remission of Cushing's disease due to pituitary basophil adenoma.
Jimenez-Alonso J; Munoz-Avila J; Jaimez L; Pérez-Jimenez F; Bellido C; Jiménez-Perepérez JA
Drug Intell Clin Pharm; 1982 Dec; 16(12):962-5. PubMed ID: 6295736
[TBL] [Abstract][Full Text] [Related]
4. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
5. Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma.
Arvat E; Giordano R; Ramunni J; Arnaldi G; Colao A; Deghenghi R; Lombardi G; Mantero F; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1998 Dec; 83(12):4207-11. PubMed ID: 9851753
[TBL] [Abstract][Full Text] [Related]
6. Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment.
van Waveren Hogervorst CO; Koppeschaar HP; Zelissen PM; Lips CJ; Garcia BM
J Clin Endocrinol Metab; 1996 Feb; 81(2):652-5. PubMed ID: 8636284
[TBL] [Abstract][Full Text] [Related]
7. Cyproheptadine may act at the pituitary in Cushing's disease: evidence from CRF stimulation.
Tucci JR; Nowakowski KJ; Jackson IM
J Endocrinol Invest; 1989 Mar; 12(3):197-200. PubMed ID: 2542391
[TBL] [Abstract][Full Text] [Related]
8. A cyproheptadine-reversible defect in ACTH control persisting after removal of the pituitary tumor in Cushing's disease.
Lankford HV; Tucker HS; Blackard WG
N Engl J Med; 1981 Nov; 305(21):1244-8. PubMed ID: 6270557
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of adrenocorticotropin (ACTH) secretion in cyclic Cushing's syndrome: evidence for more than one abnormal ACTH biorhythm.
Jordan RM; Ramos-Gabatin A; Kendall JW; Gaudette D; Walls RC
J Clin Endocrinol Metab; 1982 Sep; 55(3):531-7. PubMed ID: 6284783
[TBL] [Abstract][Full Text] [Related]
10. [Transitory remission of hypercorticism by means of cyproheptadine in a patient with Cushing syndrome].
Vetter W; Vetter H; Beckerhoff R; Würsten D; Siegenthaler W
Schweiz Med Wochenschr; 1976 Sep; 106(39):1320-2. PubMed ID: 1034340
[TBL] [Abstract][Full Text] [Related]
11. Unpredictable hypersecretion of cortisol in Cushing's disease: detection by daily salivary cortisol measurements.
Hermus AR; Pieters GF; Borm GF; Verhofstad AA; Smals AG; Benraad TJ; Kloppenborg PW
Acta Endocrinol (Copenh); 1993 May; 128(5):428-32. PubMed ID: 8391195
[TBL] [Abstract][Full Text] [Related]
12. Pituitary macroadenoma and Cushing's disease in pediatric patients: patient report and review of the literature.
Damiani D; Aguiar CH; Crivellaro CE; Galvão JA; Dichtchekenian V; Setian N
J Pediatr Endocrinol Metab; 1998; 11(5):665-9. PubMed ID: 9829219
[TBL] [Abstract][Full Text] [Related]
13. The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy.
Whitehead HM; Beacom R; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 1990 Feb; 32(2):193-201. PubMed ID: 2161298
[TBL] [Abstract][Full Text] [Related]
14. Cushing's disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment.
Verde G; Loli P; Berselli ME; Tagliaferri M; Dallabonzana D; Oppizzi G; Liuzzi A; Chiodini PG; Luccarelli G; Lodrini S
J Endocrinol Invest; 1984 Feb; 7(1):51-4. PubMed ID: 6715796
[TBL] [Abstract][Full Text] [Related]
15. Cyproheptadine in the control of Cushing's disease.
Hsu TH; Gann DS; Tsan KW; Russell RP
Johns Hopkins Med J; 1981 Aug; 149(2):77-83. PubMed ID: 6265685
[TBL] [Abstract][Full Text] [Related]
16. Cushing's disease and hyperprolactinemia due to a mixed ACTH- and prolactin-secreting pituitary macroadenoma.
Mahler C; Verhelst J; Klaes R; Trouillas J
Pathol Res Pract; 1991 Jun; 187(5):598-602. PubMed ID: 1656408
[TBL] [Abstract][Full Text] [Related]
17. Cushing's disease due to female gonadotroph adenoma of the pituitary.
Ikeda H; Yoshimoto T; Kovacs K; Horvath E
Clin Endocrinol (Oxf); 1995 Sep; 43(3):383-6. PubMed ID: 7586610
[TBL] [Abstract][Full Text] [Related]
18. Cortisol and androgen secretion in a case of Nelson's syndrome with paratesticular tumors: response to cyproheptadine therapy.
Krieger DT; Samojlik E; Bardin CW
J Clin Endocrinol Metab; 1978 Oct; 47(4):837-44. PubMed ID: 233683
[TBL] [Abstract][Full Text] [Related]
19. An unusual case of Cushing's syndrome due to bihormonal ACTH-prolactin secreting pituitary macroadenoma with rapid response to cabergoline.
Kunasegaran S; Croxson MS; Holdaway I; Murphy R
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28784879
[TBL] [Abstract][Full Text] [Related]
20. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
Casulari LA; Naves LA; Mello PA; Pereira Neto A; Papadia C
Horm Res; 2004; 62(6):300-5. PubMed ID: 15557761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
